The calculations below describe an archived October 23, 2026 snapshot of 471 providers. They summarize recorded prices and editorial corrections, not a current market census or an independently verified checkout. Later additions and changes are outside that dataset.
Three recurring billing structures complicate a monthly comparison: a prepay tier averaged into a monthly rate, a four-week cycle labeled “/month”, and a mandatory membership billed beside the medication. The question is which product, charge and purchase term the displayed figure represents. A correction can involve several of these details at once. The Male Excel review separates membership fees from the selected prescription’s price. The Kova review separates prepaid programs from monthly commitments and cancellation repricing.
Use the Queen RX review to compare cash due at purchase with a monthly budget. Read the PrescribedRX review alongside it, paying attention to the difference between a supply commitment and permission to renew. The TRT Kingdom review separates four-month offers from lab and consultation charges.
What the archived roster records
Across 471 sellers and 1,116 recorded price rows, 286 sellers carry a correction or qualification, filed as 539 entries. First update the base when a later source check records a changed price, then compare that recorded base with the amount normalized for the identified product and purchase terms. That second step raises 271 rows across 136 sellers by a median $41 a month — 1.22 times the base, or $492 over a year. Another 153 numeric prices across 92 sellers become uncomputable because required charges, conflicting schedules or product matches cannot be resolved. Forty-nine product rows are excluded: forty-eight unconfirmed and one unsupported. The snapshot contains 1,067 nonexcluded rows, including 217 blanks, including sixty-four rows without a numeric base. Unconfirmed does not mean unavailable.
Published-price changes are a separate comparison: 60 recorded quotes rose and 125 fell on later source checks; none was withdrawn through that repricing step. Those recorded changes are not counted as normalization caused by a fee or payment term. These are published-source comparisons, not a walked checkout. One separate period normalization lowers a five-week charge to its calendar-month equivalent; it is not a seller price cut. The methodology keeps that distinction.
Corrections involving three billing structures
The applied correction’s explanation and its sourced payment intervals, including separate required charges, group changes involving a fee, a prepaid purchase or a billing period other than one calendar month. The groups describe whole corrections, including product and eligibility changes; their medians do not isolate what a fee alone costs. Term-related evidence appears in 101 entries across 54 sellers. Among the 93 upward adjustments assigned to this group, the median is $19 a month, or 8.4%. Independently, a four-week period is 28 days. Comparing it with an average calendar month raises the equivalent rate by about 8.7%; it does not predict how many invoices fall within a particular year.
Fee-related explanations appear in 92 entries across 49 sellers. The 64 upward adjustments assigned here have a median of $75.10 a month, or 38.7%. This includes mixed corrections and is not an estimate of a membership fee by itself. Prepay-related wording appears in 83 entries across 50 sellers; its 69 upward adjustments have a median of $54, or 33.5%. A lower advertised equivalent can therefore describe a different commitment, even when the underlying medicine has not changed.
The term-related group has the smallest median adjustment here, while fee-related and prepay-related groups are larger. Mixed changes are assigned to fee, then prepay, then term groups. That comparison does not establish why a seller chose its headline or separate the effects of overlapping terms. The mechanics of membership billed monthly, annually or at signup are worked into a comparable figure in the annual-cost article.
The iThriveMD review sets four-week renewals beside longer prepaid packages, while the Garcia review distinguishes starting care from maintenance and calendar-year VIP commitments. Compare the payable term and eligibility phase before treating either offer as a month-to-month medication purchase. The Docberry review separates program totals from advertised monthly financing payment options.
The LIV by WellNow review illustrates a medication bundle with dose tiers and different payment periods. The JRNYS review separates care membership from the pharmacy bill. Establish what each payment includes before comparing the displayed rates: a longer medication plan and a recurring care fee answer different cost questions.
22 explanations name more than one structure. Each is assigned once, with fee-related wording taking precedence, then prepay, then term-related evidence. Negated statements such as “no membership fee” do not count as affirmative fee evidence. A fourth group of 263 entries across 160 sellers lacks those structural tags. Its 45 upward adjustments have a median of $50, or 30.3%. Low-dose or introductory figures, product uncertainty and unpriced requirements also complicate a comparison; the three billing groups are not a complete account.
The structures also stack, which is why the largest single corrections in this file are not the largest single fees. A seller billing a four-week cycle and charging a separate membership needs both terms accounted for. Some older recorded conversions use thirteen fills divided across twelve months: a 52-week comparison 8.3% above one fill. An average-calendar-month conversion is about 8.7% higher. These conventions do not predict dated cash payments. Add any separate fee on its own billing schedule. A twelve-month prepay average is also a different purchase from a month-to-month plan. The LifeVine Wellness review distinguishes monthly equivalents from the selected purchase commitment. The largest recorded multiplier in the archive belongs to none of that, though: a headline of $25 compared with a calculated $378, 15.1 times the advertised figure, because the $25 is an insured copayment with a capped monthly saving and the archived correction uses a published $349 self-pay four-pen box and a 28-day supply conversion. An insured copayment and a self-pay supply are different purchase terms. The Protocole review separates four-week product prices from an unspecified initiation fee. The Freeley review separates plan-length pricing from refill cancellation and refund conditions.
The ReadyRx review separates an introductory payment from the ongoing medicine charge. The Refills review compares a thirty-day supply with longer-plan equivalents. For either offer, compare the selected supply and total payment with the renewal terms, rather than treating every displayed monthly figure as the same purchase.
The Premium Health review compares base membership and higher-dose charges. The ElixaMD review distinguishes an introductory prescription offer, later refills and a separate branded-drug membership. Establish the continuing cost for the selected treatment before comparing the smallest figures.
Use the SkyRx review to check the total commitment, payment dates and refund terms before comparing a monthly equivalent.
Use the SexyMD review to check whether the billed period, delivery interval and supplied quantity describe the same purchase before calculating a monthly equivalent.
Use the Southern Vitality and Weight Loss review to compare the supplied period, total commitment and renewal terms before ranking a monthly equivalent alongside a shorter purchase.
Use the TeleZen MD review to compare the billed term, total commitment and renewal charge before treating a monthly equivalent as a one-month payment.
Use the Heros Health review and Jently review to compare the amount due, supplied period and next payment date before treating a monthly equivalent as a one-month purchase.
Use the Independent Wellness review and Livv review to check the selected plan, continuing charge and cancellation deadline before comparing the smallest displayed figures.
The lowest quartile has the largest recorded percentage adjustment
Split the 271 normalized rows into ranked groups of 68, 68, 68 and 67 by the figure their seller advertised, and the uplift runs backwards against the headline. Rows advertised between $25 and $135 gain a median of 46.5%. Rows between $135 and $179 gain 27.9%. Rows between $179 and $249 gain 18.8%, and the final quartile, $249 to $1,299, gains 8.8%. The decline is monotonic across all four, and the lowest-price quartile carries more than five times the percentage adjustment of the dearest. Equal advertised prices can fall in neighboring quartiles because these are similarly sized ranked groups rather than distinct price bands.
These quartiles describe records with upward adjustments. They do not show which sellers deliberately omitted charges or how other offers compare. 75 rows advertised under $150 land at or above $150 once the arithmetic is done, and 81 rows advertised under $200 land at or above $200 — each one crossing the threshold a board or a filter is likely to be sorted on, and many of them crossing the one a price-capped board is built around.
Historical group medians answer a different question
Here is the part that should complicate any use of a summary statistic. This next comparison uses historical recorded prices, including those later repriced, rather than the current-base normalization above. Across rows originally recorded as compounded semaglutide injections, the median advertised figure is $175 over 461 rows. After repricing and corrections are applied the median is $179 over 351 retained compounded injection rows. Rows without a usable price or corrected to a different product or supply category no longer belong in that group. For compounded tirzepatide injection the median moves from $240 over 421 rows to $249 over 342.
Those historical field medians move four and nine dollars; neither measures normalization from the current published base. The latter comparison has a median adjustment of $41 a month, or $492 over a year, across its 271 upward adjustments. The two baselines answer different questions. The full distribution behind the field medians is in the price-variation article.
Use the WeightlessRx review to compare the full payment, supplied course and next charge date before treating a divided package amount as a monthly bill.
Compare the Lumen Meds review and Maves review with the offer you intend to buy. Write down how much you must commit and what happens if you stop, then decide whether the apparent saving is worth that obligation.
The GOAL.MD review explains why cancellation and payment rules need to be checked for the chosen service.
Persistence and a longer purchase term
A 2025 observational study examined 15,811 commercially insured US adults starting Wegovy single-dose pens during June 2021–December 2023. It reported 46% discontinuation by month five and 48% among those starting after October 2023 supply stabilization.[1]
Reported discontinuation ranged from 41% in the lowest copayment quintile ($1–$54 monthly) to 51% in the highest ($161–$1,460). These associations do not compare prepaid and monthly plans or predict a cash-pay buyer’s year-long treatment.[1]
Before prepaying, ask what happens to the unused purchase if treatment changes or stops. Compare the selected contract’s refund and cancellation terms with your budget. How the two payment routes compare is in the insurance article.
Renewal arrangements deserve the same attention as the opening price. The WeightCare review separates starter purchases, continuation doses and prepaid terms. The ReflexMD review explains its automatic subscription renewal and cancellation cutoffs. By comparison, the LifeRx review describes a service whose terms require the patient to request monthly continuation. Establish whether another payment is automatic, how much treatment it buys and how to stop it before comparing a discounted equivalent. The KIN Health review distinguishes monthly offers from longer packages and refills.
The G-Plans review separates its nutrition subscriptions from medication care. Confirm which service a subscription buys before using its price in a GLP-1 comparison.
When a figure covers care rather than medication
A care membership, consultation or program fee may cover a different service from a medication purchase. Check what the selected amount buys before putting it beside a drug price. A fee-only quote does not establish the combined cost, and a missing amount in a record does not establish that the seller publishes no price elsewhere. The Tummala Health review separates membership fees from conditionally advertised medication prices. The Ambiante review separates ongoing care membership from the selected medication agreement.
If a required charge or the selected product remains unresolved, leave the comparable total unknown rather than treating a partial figure as complete. Ask which detail remains unresolved for the selected offer. A reader or seller can raise a specific issue through the corrections log.
What this does not establish
These are correction records, not an examination census. Of 471 sellers, 312 have correction or exemption records: 286 with corrections and 26 with exemptions. Those exemptions include prices already accounting for a required fee and statements that no fee exists. The other 159 have no such record. Record absence does not establish whether a service was examined or whether its medication quote is complete.
Nor does any of this describe the product. Compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed.[2] An August–October 2025 cross-sectional secret-shopper study examined 75 clinics and medical spas in purposively selected West Virginia and Oklahoma. It identified 23 compounding suppliers: 4 of 21 lacked sterile-compounding licenses, and 3 of 22 had faced state disciplinary action since 2023.[3] Those sample findings do not describe every provider or establish a relationship between billing and pharmacy characteristics. Price arithmetic alone does not verify the pharmacy assigned to a prescription.
Ask for the selected product, total amount due, covered supply period, separate required charges and minimum purchase term. Check future charges, renewal authorization, cancellation and refund terms separately. A monthly equivalent is a comparison, not necessarily an installment or an invoice. Running a specific quote with its stated assumptions through the cost calculator can estimate a year’s cost, and the sellers that hold one rate across every dose are collected on the flat-pricing board.
For concrete plan comparisons, the Henry Meds review separates monthly charges from prepaid supply options and cancellation obligations. The Edessa review compares the provider’s published one-, three-, and six-month tiers. The Brello Health review sets the payment schedule beside the intake process, so you can compare the timing as well as the total. A lower monthly equivalent needs to be read alongside the amount and commitment required.